Injections, Intradermal

6 trials

Sponsors

Center of Molecular Immunology (CIM)

Conditions

Advanced Lung Cancer Non-small Cell Lung CancerAdvanced Lung Cancer Small Cell Lung CancerAdvanced non small cell lung cancerBreast carcinoma in stage IV or progressive metastatic diseaseColon adenocarcinoma phase IV or evolvable metastatic diseaseLung Cancer

Early Phase 1

Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory

Active, not recruitingRPCEC00000279

Center of Molecular Immunology (CIM)Advanced non small cell lung cancer

Start: 2018-07-09Updated: 2026-03-30

Phase 2

1E10 anti-idiotype vaccine, metastatic colon, phase II.

Active, not recruitingRPCEC00000006

Center of Molecular Immunology (CIM)Colon adenocarcinoma phase IV or evolvable metastatic disease

Start: 2002-07-19Target: 40Updated: 2026-03-30

1E10 anti-idiotype vaccine, metastatic breast cancer, phase II

Active, not recruitingRPCEC00000008

Center of Molecular Immunology (CIM)Breast carcinoma in stage IV or progressive metastatic disease

Start: 2003-09-15Target: 80Updated: 2026-03-30

Anti-idiotype 1E10 vaccine in advanced non- small cell lung (NSCLC) patients

Active, not recruitingRPCEC00000009

Center of Molecular Immunology (CIM)Advanced Lung Cancer Non-small Cell Lung Cancer

Start: 2006-09-27Target: 176Updated: 2026-03-30

Anti-idiotype 1E10 vaccine in the treatment of patients with small cell lung (SCLC) patients

Active, not recruitingRPCEC00000010

Center of Molecular Immunology (CIM)Advanced Lung Cancer Small Cell Lung Cancer

Start: 2005-03-03Target: 88Updated: 2026-03-30

Phase 3

Safety and efficacy of VAXIRA® in advanced NSCLC patients not progressing after first line chemotherapy. Phase III.

Active, not recruitingRPCEC00000336

Center of Molecular Immunology (CIM)Lung Cancer

Start: 2020-11-30Target: 264Updated: 2026-03-30